RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

Inclusion criteria

• An IEC/IRB approved written informed consent signed and dated by the patient or by parent(s) or a legally acceptable representative. The consent form or a specific assent form, where required, will be signed and dated by minors.
• Documented Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT), Pulmonary/Cardiac Transplant, Pulmonary Transplant or Liver Transplant within the 2 years prior to randomization to the study drug.
• Male/Female patients age: (Pediatric) ≥2 years and <16 years at the time of informed consent.
• Male/Female patients age: (Adult) ≥ 16 years and ≤ 65 years at the time of informed consent.
• Patient must have an URTI as defined by Respiratory Assessment Score (RAS)=1.
• Patients must be actively taking at least one immunosuppressive agent.
• Patients must have a positive RSV RT-PCR at the time of the randomization procedures.
• Female patients must be of non-childbearing potential or have a negative pregnancy test prior to study start and be deemed not at risk of becoming pregnant by adherence to a reliable contraceptive method for the duration of the study. Females of non-childbearing potential are defined as women who have had a hysterectomy, bilateral oophorectomy, tubal ligation or who have been post-menopausal for at least two years, or are considered to be sterile due to recent chemotherapy.
• Female patients who are not breast-feeding.
• Patient/legally acceptable representative considered as reliable and capable of adhering to the protocol (e.g. able to understand and complete diaries and questionnaires), visit schedules or treatment regimen according to the judgment of the Investigator.

Exclusion criteria

• Documented RSV lower respiratory tract infection (respiratory assessment score is greater than 1) as determined by the site investigators or research staff.
• Requirement for mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure or other mechanical respiratory or cardiac support
• Unstable respiratory status so severe that survival is not expected for longer than 6 months.
• End organ dysfunction resulting in anticipated survival of less than 6 months.
• Known to be HIV positive.
• Administration of any RSV specific products, including palivizumab (Synagis®) in the 3 months prior to randomization procedures.
• Previous, current, or planned administration of an investigational RSV vaccine.
• Known hypersensitivity to immunoglobulin.
• Known Immunoglobulin (IgA) deficiency
• Known renal impairment requiring any form of dialysis (HD, PD, CRRT).
• Known hemodynamically significant congenital heart disease.
• Previous poor compliance with visit schedules.
• Severe medical, neurological or psychiatric disorders or laboratory values which may have an impact on the safety of the patient.
• Concurrent participation in other investigational drug product studies; any exception must be approved by the ADMA Biologics Medical Director.